SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinomas (RCC) who have failed standard RCC therapies.
Read more at globenewswire.comAllogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
